133626-73-0 Usage
Chemical class
Benzodiazepine derivative
Molecular structure
Complex, containing an ethyl group, a methyl group, and a trifluoromethyl group
Ring system
Pyrido-benzodiazepine
Central nervous system effects
Depressant and sedative properties
Trifluoromethyl group
May contribute to enhanced pharmacological activity or altered physicochemical properties
Potential applications
Pharmaceutical industry for the development of new therapeutic agents targeting the central nervous system
Molecular weight
Approximately 375.37 g/mol
Appearance
Likely a solid, based on its molecular weight and complexity
Solubility
Not explicitly mentioned, but may be influenced by the presence of the trifluoromethyl group
Stability
Not explicitly mentioned, but the presence of the trifluoromethyl group may affect stability
Synonyms
Not provided, but may include variations in naming conventions or alternative names for the compound
Hazards
Not explicitly mentioned, but as a benzodiazepine derivative, it may have potential risks associated with its central nervous system effects
Regulatory status
Not mentioned, but may be subject to specific regulations depending on its intended use and classification as a pharmaceutical compound
Check Digit Verification of cas no
The CAS Registry Mumber 133626-73-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,3,6,2 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 133626-73:
(8*1)+(7*3)+(6*3)+(5*6)+(4*2)+(3*6)+(2*7)+(1*3)=120
120 % 10 = 0
So 133626-73-0 is a valid CAS Registry Number.
133626-73-0Relevant articles and documents
Novel Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. 1. Tricyclic Pyridobenzo- and Dipyridodiazepinones
Hargrave, Karl D.,Proudfoot, John R.,Grozinger, Karl G.,Cullen, Ernest,Kapadia, Suresh R.,et al.
, p. 2231 - 2241 (2007/10/02)
Novel pyridobenzodiazepinones (I), pyridobenzodiazepinones (II), and dipyridodiazepinones (III) were found to inhibit human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in vitro at concentrations as low as 35 nM.In all three series, small substituents (e.g., methyl, ethyl, acetyl) are preferred at the lactam nitrogen, whereas slightly larger alkyl moieties (e.g., ethyl, cyclopropyl) are favored at the other (N-11) diazepinone nitrogen.In general, lipophilic substituents are preferred on the A ring, whereassubstitution on the C ring generally reduces potency relative to the corresponding compounds with no substituents on the aromatic rings.Maximum potency is achieved with methyl substitution at the position ortho to the lactam nitrogen atom; however, in this case an unsubstituted lactam nitrogen is preferred.Additional substituents on the A ring can be readily tolerated.The dipyridodiazepinone derivative 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyridodiazepin-6-one (96, nevirapine) is a potent (IC50 = 84 nM) and selective non-nucleoside inhibitor of HIV-1 reverse transcriptase, and has been chosen for clinical evaluation.
